James Antonopoulos has joined Roth Capital Partners as managing director, co-head of healthcare investment banking.Read More
Cantor Fitzgerald expanded its healthcare equity research team with the additions of Louise Chen and Travis Steed.Read More
Closely-held Roth Capital Partners named Eric Cheng as managing director, head of healthcare investment banking.Read More
Duff & Phelps has added managing director Phil Smith and director Adam Stormoen to its healthcare M&A advisory practice in Minneapolis.Read More
Oppenheimer & Co., a unit of Oppenheimer Holdings (NYSE:OPY), has hired a new life sciences team, led by Michael Margolis, to join the firm's healthcare investment banking group.Read More
John Calcagnini has joined Stout Risius Ross as managing director in the investment banking group’s healthcare industry practice.Read More
Joseph Pantginis has joined Rodman & Renshaw in equity research as a managing director covering biotechnology.Read More
Jeff Sacher has joined Aegis Capital to lead the firm's global healthcare effort as a managing director.
Previously, Mr. Sacher was a senior banker at Goldman Sachs, Needham and Brean Capital. In addition, he has served as CFO for Viacell, a stem cell company purchased by PerkinElmer.Read More
Shawn Aspden, a 20-year veteran of the Canadian capital markets, has joined Bloom Burton & Co. as managing director. Mr. Aspden recently served was vice chairman and head of North American institutional equity sales at GMP Securities.
In the role of managing director, Mr. Aspden will expand Bloom Burton’s ability to serve Canadian institutional investors as they consider the important pharmaceutical, biotechnology and healthcare sectors. He will broaden the awareness and distribution of Bloom Burton’s investment banking and advisory capabilities, award-winning equity research, and events such as the firm’s flagship Bloom Burton Healthcare Investor Conference.Read More
Shaunak Deepak has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.
Mr. Deepak previously was a VP and biotech analyst with Jefferies since 2009. He also has been an associate in the life sciences equity research departments of Piper Jaffray, Rodman & Renshaw and Stifel, Nicolaus.Read More